Journal
BIOESSAYS
Volume 38, Issue 4, Pages 344-354Publisher
WILEY
DOI: 10.1002/bies.201500118
Keywords
abdominal pain; cannabinoid receptors; gastrointestinal motility; GPCR signaling; inflammatory bowel disease; opioid receptors; RGS proteins; serotonin receptors
Categories
Funding
- Medical University of Lodz [502-03/1-156-02/502-14-140, 503/1-156-04/503-01]
- National Science Centre [UMO-2013/11/N/NZ7/02354, UMO-2015/16/T/NZ7/00031, UMO-2013/11/B/NZ7/01301, UMO-2014/13/B/NZ4/01179]
- National Institutes of Health [DA026405, DA036596]
- Polpharma Scientific Foundation
Ask authors/readers for more resources
Regulators of G protein signaling (RGS) proteins provide timely termination of G protein-coupled receptor (GPCR) responses. Serving as a central control point in GPCR signaling cascades, RGS proteins are promising targets for drug development. In this review, we discuss the involvement of RGS proteins in the pathophysiology of the gastrointestinal inflammation and their potential to become a target for anti-inflammatory drugs. Specifically, we evaluate the emerging evidence for modulation of selected receptor families: opioid, cannabinoid and serotonin by RGS proteins. We discuss how the regulation of RGS protein level and activity may modulate immunological pathways involved in the development of intestinal inflammation. Finally, we propose that RGS proteins may serve as a prognostic factor for survival rate in colorectal cancer. The ideas introduced in this review set a novel conceptual framework for the utilization of RGS proteins in the treatment of gastrointestinal inflammation, a growing major concern worldwide.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available